Verve Therapeutics (NASDAQ:VERV) Rating Lowered to Hold at Canaccord Genuity Group
Verve Therapeutics (NASDAQ:VERV – Get Free Report) was downgraded by analysts at Canaccord Genuity Group from a “strong-buy” rating to a “hold” rating in a report issued on Tuesday, Marketbeat Ratings reports. They currently have a $13.00 price target on the stock, down from their previous price target of $39.00. Canaccord Genuity Group’s price target […]
Verve Therapeutics (NASDAQ:VERV – Get Free Report) was downgraded by analysts at Canaccord Genuity Group from a “strong-buy” rating to a “hold” rating in a report issued on Tuesday, Marketbeat Ratings reports. They currently have a $13.00 price target on the stock, down from their previous price target of $39.00. Canaccord Genuity Group’s price target […]
